Rb

Syros Presents New Data from Phase 1 Trial of SY-5609 and Details Three-Pronged Combination Strategy to Advance SY-5609 in Solid Tumors and Blood Cancer

Monday, September 20, 2021 - 4:30pm

The data is being presented today in an oral presentation at the 2021 ESMO Congress.

Key Points: 
  • The data is being presented today in an oral presentation at the 2021 ESMO Congress.
  • We believe this approach could unlock significant opportunities for SY-5609 and achieve the transformative potential of CDK7 inhibition for people with difficult-to-treat cancers.
  • Patients had been heavily pre-treated with as many as eight prior therapies and a median of four prior therapies.
  • Syros plans to initiate an expansion cohort evaluating SY-5609 in combination with chemotherapy for the treatment of pancreatic cancer in the fourth quarter of 2021.

Tachyon Announces Presentation at the 2021 ESMO Annual Meeting

Friday, September 17, 2021 - 1:00pm

Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a research and development biotechnology company, announces an abstract presentation of the Companys lead product candidate, TACH101, at the European Society of Medical Oncology (ESMO) Annual Meeting.

Key Points: 
  • Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a research and development biotechnology company, announces an abstract presentation of the Companys lead product candidate, TACH101, at the European Society of Medical Oncology (ESMO) Annual Meeting.
  • ESMO is being held virtually from September 16-21, 2021.
  • Triple negative breast cancer represents nearly 20% of all breast cancers and is a highly aggressive subtype that continues to have poor prognosis due to lack of effective treatments, stated Frank Perabo, MD, PhD, CEO of Tachyon Therapeutics.
  • Tachyon Therapeutics, Inc. is an R&D focused biotechnology company advancing novel, first-in-class therapeutics for the treatment of advanced cancers.

Portofino Mobilizes Team to Expand Channel Sampling Program - Allison Lake North Lithium Property

Tuesday, September 14, 2021 - 1:25pm

The team is expanding on the initial exploration program and carrying out additional systematic channel sampling where encouraging Lithium ("Li") and Tantalum ("Ta") values were recently discovered.

Key Points: 
  • The team is expanding on the initial exploration program and carrying out additional systematic channel sampling where encouraging Lithium ("Li") and Tantalum ("Ta") values were recently discovered.
  • Initial grab sampling by Portofino (NR Sept 7, 2021) returned values up to 398 ppm Li, 90.5 ppm Cesium, 1040 ppm Rubidium and 135 ppm Ta.
  • Allison Lake North property regional geological location.
  • Portofino's green energy projects include the Allison Lake North (Ontario) Lithium project, and the Yergo Lithium property which encompasses the entire Aparejos Salar, located within the world-renowned "Lithium Triangle" in Argentina.

Portofino Receives Encouraging Sampling Results, Discovers New Targets - Allison Lake North Lithium Property

Tuesday, September 7, 2021 - 1:30pm

Sampling in the northwest portion of the property returned the highest values where pegmatitic textures were encountered within the Allison Lake Batholith.

Key Points: 
  • Sampling in the northwest portion of the property returned the highest values where pegmatitic textures were encountered within the Allison Lake Batholith.
  • Sampling locations on the Allison Lake Lithium property.
  • Of note is Frontier Lithium Inc.'s PAK Lithium deposit along the 'Electric Avenue' which contains one of North America's highest-grade, large tonnage hard-rock lithium resources.
  • Portofino's green energy projects include the Allison Lake North (Ontario) Lithium project, and the Yergo Lithium property which encompasses the entire Aparejos Salar, located within the world-renowned "Lithium Triangle" in Argentina.

Syros Announces Agreement with Roche to Evaluate SY-5609 as Part of a Novel Combination for Treatment of Colorectal Cancer

Thursday, August 5, 2021 - 12:15pm

Preclinical data has shown that CDK7 inhibition enhances the anti-tumor activity of PD-L1 inhibition, providing a strong rationale for combining SY-5609 and atezolizumab.

Key Points: 
  • Preclinical data has shown that CDK7 inhibition enhances the anti-tumor activity of PD-L1 inhibition, providing a strong rationale for combining SY-5609 and atezolizumab.
  • Notably, this trial marks the first clinical investigation of a CDK7 inhibitor with an immunotherapy, and we look forward to working with Roche to evaluate the potential of this novel combination in patients with BRAF-mutant colorectal cancer.
  • Under the terms of the agreement, Roche will sponsor and conduct the Phase 1/1b study to evaluate the safety, tolerability and preliminary efficacy of the combination and will assume all costs associated with the study.
  • In exchange for providing SY-5609, Syros will receive access to the data on SY-5609 in combination with atezolizumab.

Maidbot Closes Series B Round Led by RB, Makers of Lysol

Monday, November 16, 2020 - 4:30pm

The funding is being led by RB (Reckitt Benckiser), a leading health, hygiene and nutrition company and the makers of many world-renowned brands including Lysol, Dettol, Harpic, Finish and Mucinex.

Key Points: 
  • The funding is being led by RB (Reckitt Benckiser), a leading health, hygiene and nutrition company and the makers of many world-renowned brands including Lysol, Dettol, Harpic, Finish and Mucinex.
  • Through this investment and our partnership, Maidbot and RB will enable more businesses to reassure customers on cleanliness and deliver an enhanced hygienic experience."
  • Octave Ventures, a leading venture fund supported by Peter Thiel that led Maidbot's Series A round, also participated in the most recent funding round.
  • In addition to Octave Ventures, several VCs alongside hospitality and commercial real estate executives and family offices participated in the round.

RB contributes $3.8 billion to US economy

Tuesday, July 28, 2020 - 2:59pm

A global leader in health, hygiene, and nutrition products, RB contributed $3.8 billion to the US economy last year, stimulating an additional $1.4 million in expenditure for every $1 million in GDP the company generates.

Key Points: 
  • A global leader in health, hygiene, and nutrition products, RB contributed $3.8 billion to the US economy last year, stimulating an additional $1.4 million in expenditure for every $1 million in GDP the company generates.
  • Rahul Kadyan, EVP, North America, Hygiene, RB commented: "We have a long and proud history of creating innovative products for individuals, families and communities.
  • The report, Creating a Cleaner and Healthier Economy - The Economic Impact Of Reckitt Benckiser In The US was produced by Oxford Economics and commissioned by RB.
  • RB* is driven by its vision to protect, heal and nurture in the relentless pursuit of a cleaner, healthier world.

Carrols Restaurant Group, Inc. Names Markus Hartmann as General Counsel

Friday, February 14, 2020 - 12:00pm

Carrols Restaurant Group, Inc. (Carrols or the Company) (Nasdaq: TAST) today announced that it has appointed Markus Hartmann as the Companys Vice President and General Counsel effective February 18, 2020.

Key Points: 
  • Carrols Restaurant Group, Inc. (Carrols or the Company) (Nasdaq: TAST) today announced that it has appointed Markus Hartmann as the Companys Vice President and General Counsel effective February 18, 2020.
  • Accordino concluded, We would also like to thank Bill Myers for his 19 years at Carrols and for serving as our General Counsel since 2012.
  • Mr. Hartmann previously served as the North American General Counsel for Sandoz, Inc. (a division of Novartis) (NYSE: NVS), as well as the European and North American General Counsel for Reckitt Benckiser (LSE:RB) while living and working as an expatriate in the Netherlands.
  • Carrols is one of largest restaurant franchisees in the United States, and currently operates 1,100 restaurants.

RB Partners With Veolia to Drive a Circular Plastics Economy

Wednesday, November 13, 2019 - 5:00pm

Reckitt Benckiser (RB) and Veolia announced today a new joint partnership to drive the shift toward a circular plastics economy.

Key Points: 
  • Reckitt Benckiser (RB) and Veolia announced today a new joint partnership to drive the shift toward a circular plastics economy.
  • To accelerate the circular plastics economy, a team of 20 experts from RB and Veolia are also working to develop enhanced collection systems, driving behavior change to aid consumer sorting habits and to improve recycling from households.
  • The partnership between Veolia and RB Hygiene Home brings together our complementary capabilities to drive a positive contribution to the circular economy.
  • We are working hand-in-hand with RB to develop packaging with greater recycled content and improved recyclability for the RB groups consumers, says Antoine Frrot, Chairman and CEO of Veolia.

Top CEOs to Lead and Share Best Practices for Leadership, Diversity and Success at 2019 Middle East Edition of Break the ceiling touch the sky(R)

Wednesday, March 13, 2019 - 5:00am

CommentedShahzeb Mahmood, Regional Director and GM, MENAP, Reckitt Benckiser, "At RB, we actively seek to integrate diversity into our business.

Key Points: 
  • CommentedShahzeb Mahmood, Regional Director and GM, MENAP, Reckitt Benckiser, "At RB, we actively seek to integrate diversity into our business.
  • This is for us the most obvious continuing enabler to unlock the full potential of our people, our brands and our businesses.
  • We are proud to be a Platinum sponsor of the 2019 Middle East Edition of the summit."
  • The move to bring the summit back to Dubai, UAE has been inspired by the UAE's commitment to gender diversity.